Detailed information for compound 433655

Basic information

Technical information
  • TDR Targets ID: 433655
  • Name: 4-[[4-[4-[(E)-2-cyanoethenyl]-2-methylanilino ]pyrimidin-2-yl]amino]benzonitrile
  • MW: 352.392 | Formula: C21H16N6
  • H donors: 2 H acceptors: 4 LogP: 4.18 Rotable bonds: 5
    Rule of 5 violations (Lipinski): 1
  • SMILES: N#C/C=C/c1ccc(c(c1)C)Nc1ccnc(n1)Nc1ccc(cc1)C#N
  • InChi: 1S/C21H16N6/c1-15-13-16(3-2-11-22)6-9-19(15)26-20-10-12-24-21(27-20)25-18-7-4-17(14-23)5-8-18/h2-10,12-13H,1H3,(H2,24,25,26,27)/b3-2+
  • InChiKey: FHPSDGUUMXPNGR-NSCUHMNNSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 4-[[4-[4-[(E)-2-cyanovinyl]-2-methyl-anilino]pyrimidin-2-yl]amino]benzonitrile
  • 4-[[4-[4-[(E)-2-cyanovinyl]-2-methylanilino]-2-pyrimidinyl]amino]benzonitrile
  • 4-[[4-[[4-[(E)-2-cyanoethenyl]-2-methyl-phenyl]amino]pyrimidin-2-yl]amino]benzenecarbonitrile
  • 4-[[4-[[4-[(E)-2-cyanoethenyl]-2-methylphenyl]amino]pyrimidin-2-yl]amino]benzonitrile
  • 4-[[4-[[4-[(E)-2-cyanovinyl]-2-methyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile
  • 4-[[4-[[4-[(E)-2-cyanovinyl]-2-methylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
  • 4-[[4-[[4-[(E)-2-cyanoethenyl]-2-methyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile
  • AIDS169067
  • 4-{4-[4-((E)-2-Cyano-vinyl)-2-methyl-phenylamino]-pyrimidin-2-ylamino}-benzonitrile
  • AIDS-169067

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Brugia malayi Integrin alpha pat-2 precursor 0.0499 0.1824 1
Loa Loa (eye worm) hypothetical protein 0.0199 0.0278 0.0865
Echinococcus granulosus integrin alpha ps 0.0224 0.0405 0.0405
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Loa Loa (eye worm) matrixin family protein 0.0442 0.1529 0.4754
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Schistosoma mansoni integrin alpha-ps 0.0224 0.0405 0.2218
Brugia malayi Matrixin family protein 0.0199 0.0278 0.1526
Mycobacterium leprae PROBABLE HYDROLASE 0.0243 0.0502 1
Schistosoma mansoni integrin alpha 0.0499 0.1824 1
Leishmania major hypothetical protein, conserved 0.0757 0.3155 1
Brugia malayi Hemopexin family protein 0.0282 0.0708 0.3879
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Mycobacterium ulcerans hydrolase 0.0243 0.0502 1
Schistosoma mansoni hypothetical protein 0.0282 0.0708 0.3879
Mycobacterium tuberculosis Probable peptidoglycan hydrolase 0.0243 0.0502 1
Brugia malayi Matrixin family protein 0.0199 0.0278 0.1526
Loa Loa (eye worm) hypothetical protein 0.0392 0.1271 0.3951
Loa Loa (eye worm) matrix metalloproteinase 0.0199 0.0278 0.0865
Echinococcus multilocularis integrin alpha 3 0.0382 0.1224 0.1224
Giardia lamblia Fructose-bisphosphate aldolase 0.0319 0.0895 1
Treponema pallidum fructose-bisphosphate aldolase 0.0319 0.0895 0.5
Loa Loa (eye worm) hypothetical protein 0.0243 0.0502 0.1561
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Echinococcus multilocularis integrin alpha ps 0.0224 0.0405 0.0405
Trypanosoma brucei RNA helicase, putative 0.0167 0.0111 1
Entamoeba histolytica fructose-1,6-bisphosphate aldolase, putative 0.0319 0.0895 1
Onchocerca volvulus Matrix metalloproteinase homolog 0.0442 0.1529 1
Echinococcus multilocularis integrin alpha ps 0.0224 0.0405 0.0405
Echinococcus multilocularis matrix metallopeptidase 7 (M10 family) 0.0724 0.2986 0.2986
Trypanosoma cruzi hypothetical protein, conserved 0.0729 0.3011 1
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Entamoeba histolytica fructose-1,6-bisphosphate aldolase, putative 0.0319 0.0895 1
Onchocerca volvulus 0.0282 0.0708 0.3431
Loa Loa (eye worm) hypothetical protein 0.0275 0.0671 0.2084
Loa Loa (eye worm) hypothetical protein 0.0199 0.0278 0.0865
Brugia malayi Matrixin family protein 0.0199 0.0278 0.1526
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Brugia malayi Integrin alpha cytoplasmic region family protein 0.0377 0.1197 0.6564
Schistosoma mansoni hypothetical protein 0.0167 0.0111 0.0607
Loa Loa (eye worm) hypothetical protein 0.0377 0.1197 0.3722
Echinococcus multilocularis DNA dependent protein kinase catalytic subunit 0.2084 1 1
Echinococcus granulosus matrix metallopeptidase 7 M10 family 0.0724 0.2986 0.2986
Loa Loa (eye worm) matrixin family protein 0.0482 0.1735 0.5392
Loa Loa (eye worm) hypothetical protein 0.0199 0.0278 0.0865
Brugia malayi Matrixin family protein 0.0482 0.1735 0.9511
Loa Loa (eye worm) integrin alpha pat-2 0.0769 0.3217 1
Echinococcus granulosus integrin alpha 3 0.0382 0.1224 0.1224
Onchocerca volvulus Matrilysin homolog 0.0442 0.1529 1
Brugia malayi Matrixin family protein 0.0199 0.0278 0.1526
Schistosoma mansoni matrix metallopeptidase-7 (M10 family) 0.0199 0.0278 0.1526
Toxoplasma gondii target of rapamycin (TOR), putative 0.0145 0 0.5
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Brugia malayi Matrix metalloprotease, N-terminal domain containing protein 0.0243 0.0502 0.2753

Activities

Activity type Activity value Assay description Source Reference
CC50 (ADMET) > 25000 nM Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay ChEMBL. 17223230
CC50 (ADMET) > 25000 nM Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay ChEMBL. 17223230
EC50 (functional) = 0.6 nM Antiviral activity against HIV1 LAI with RT K103N mutation in MT4 cells by EGFP based replication assay ChEMBL. 17223230
EC50 (functional) = 0.9 nM Antiviral activity against wild type HIV1 LAI infected in MT4 cells by EGFP based replication assay ChEMBL. 17223230
EC50 (functional) = 1.2 nM Antiviral activity against HIV1 LAI with RT F227C mutation in MT4 cells by EGFP based replication assay ChEMBL. 17223230
EC50 (functional) = 1.2 nM Antiviral activity against HIV1 LAI with RT F227C and V106A mutation in MT4 cells by EGFP based replication assay ChEMBL. 17223230
EC50 (functional) = 9.2 nM Antiviral activity against HIV1 LAI with RT L100I mutation in MT4 cells by EGFP based replication assay ChEMBL. 17223230
EC50 (functional) = 13.4 nM Antiviral activity against HIV1 LAI with RT Y181C mutation in MT4 cells by EGFP based replication assay ChEMBL. 17223230
EC50 (functional) = 43.6 nM Antiviral activity against HIV1 LAI with RT Y188L mutation in MT4 cells by EGFP based replication assay ChEMBL. 17223230
EC50 (functional) = 89.6 nM Antiviral activity against HIV1 LAI with RT K103N and Y181C mutation in MT4 cells by EGFP based replication assay ChEMBL. 17223230
EC50 (functional) = 478.7 nM Antiviral activity against HIV1 LAI with RT L100I and K103N mutation in MT4 cells by EGFP based replication assay ChEMBL. 17223230
Ratio CC50/EC50 (functional) > 29372 Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 LAI ChEMBL. 17223230

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.